Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2010

View Archived Issues

Alkermes to initiate clinical development of ALKS-9070 for schizophrenia in 2010

Flutiform NDA transferred from Abbott Laboratories to SkyePharma

EntreMed raises funds to further develop ENMD-2076

Bioheart begins phase I trial of genetically modified MyoCell in CHF

Merck & Co. describes discovery of novel orally bioavailable cathepsin K inhibitor MK-0674

Lux Biosciences files for approvals in the U.S. and Europe for voclosporin in uveitis

Pregabalin shows potential as a treatment for alcohol withdrawal syndrome

Novartis describes efforts to target PDK1 in oncology

Modest cellular immune responses seen with ADVAX HIV-1 candidate vaccine

XenoPort chooses Horizant as brand name for gabapentin enacarbil in the U.S.

Correlation between dopaminergic activity and pain sensitivity in healthy subjects identified

BioMarin signs stock purchase agreement to acquire LEAD Therapeutics and LT-673

OsteoGeneX claims Wnt pathway modulators for the treatment of bone diseases

Natural products with oncolytic activity identified by South African scientists

Johns Hopkins University and FASgen claim novel oncolytic agents

Novel tachykinin NK2 antagonists described by Roche

BioTime reports results of Hextend trial in unstable trauma patients

ArQule initiates phase II trial of ARQ-197 in GCT and phase I/II trial in CRC

7TM Pharma identifies novel CB1 receptor antagonists

Novel compounds for cancer therapy discovered by Japanese scientists

BioMarin reports preliminary results from phase I/II trial of BMN-110 in MPS IVA

Optimer reports topline results from phase III trial of fidaxomicin in CDI

Genmab outlicenses zanolimumab to TenX Biopharma

Mitsubishi Tanabe reports results from third quarter of 2009 ended December 31

Daiichi Sankyo submits SUN-Y7017 NDA in Japan for Alzheimer's type dementia

European Commission grants marketing authorization for silodosin in BPH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...